Orphan Drug COVID–19 Mitigation Act of 2022

Hozzl · 2022-12-29T19:03:42Z

Explore the details of House Bill 8641 Orphan Drug COVID–19 Mitigation Act of 2022 currently in Congress. Get insights into its purpose, current status, sponsors, and potential impact on Health. Stay informed on legislative developments.

12/29/2022, 7:03 PM

Summary of Bill HR 8641

Bill 117 HR 8641, also known as the Orphan Drug COVID-19 Mitigation Act of 2022, is a piece of legislation introduced in the US Congress aimed at addressing the impact of the COVID-19 pandemic on orphan drugs. Orphan drugs are medications that are developed to treat rare diseases or conditions that affect a small number of people.

The bill seeks to mitigate the impact of the COVID-19 pandemic on the development and availability of orphan drugs by providing additional funding and resources to support research and development efforts. It also aims to streamline the regulatory process for orphan drugs related to COVID-19, in order to expedite their approval and availability to patients in need.

Additionally, the bill includes provisions to ensure that orphan drugs related to COVID-19 are affordable and accessible to patients, particularly those from underserved communities. This includes measures to prevent price gouging and ensure that these medications are covered by insurance plans. Overall, the Orphan Drug COVID-19 Mitigation Act of 2022 is designed to support the development and availability of orphan drugs for COVID-19, while also ensuring that these medications are affordable and accessible to those who need them.

Congressional Summary of HR 8641

Orphan Drug COVID-19 Mitigation Act of 2022

This bill extends by 180 days the relevant periods of market exclusivity for drugs for rare diseases or conditions (i.e., orphan drugs) for which applications were submitted during the COVID-19 emergency period.

Read the Full Bill

Formatted Text PDF Formatted XML

Current Status of Bill HR 8641

Bill HR 8641 is currently in the status of Bill Introduced since August 2, 2022. Bill HR 8641 was introduced during Congress 117 and was introduced to the House on August 2, 2022. Bill HR 8641's most recent activity was Referred to the House Committee on Energy and Commerce. as of August 2, 2022

Bipartisan Support of Bill HR 8641

Total Number of Sponsors

Democrat Sponsors

Republican Sponsors

Unaffiliated Sponsors

Total Number of Cosponsors

Democrat Cosponsors

Republican Cosponsors

Unaffiliated Cosponsors

Policy Area and Potential Impact of Bill HR 8641

Primary Policy Focus

Health

Alternate Title(s) of Bill HR 8641

Orphan Drug COVID–19 Mitigation Act of 2022

To mitigate the effects of the COVID-19 pandemic on incentives under the Federal Food, Drug, and Cosmetic for the development of orphan drugs, and for other purposes.